Table 5.
Summary of studies evaluating IMRT-based chemoradiation for anal cancer
| RT technique | Outcomes (y) | Median f/u (mo) | LRC (%) | CFS (%) | OS (%) | Acute G3+ GI toxicity (%) | Acute G3+ skin toxicity (%) | |
|---|---|---|---|---|---|---|---|---|
| Present study | IMRT | 3 | 20 | 90.8 | 91.3 | 91.1 | 9.6 | 11.5 |
| 3DCRT | 61.9 | 91.9 | 93.7 | 86.1 | 29.7 | 64.9 | ||
| Bazan11 | IMRT | 3 | 32 | 92 | 91 | 87.8 | 7 | 21 |
| 3DCRT | 26 | 56.7 | NR | 51.8 | 29 | 41 | ||
| Chuong12 | IMRT | 3 | 13.6 | 93.9 | 93.2 | 100 | 5 | 5 |
| Salama7 | IMRT | 1.5 | 14.5 | 83.9 | 83.8 | 93.4 | 15.1 | 37.7 |
| Pepek8 | IMRT | 2 | 19 | 85 | 91 | 100 | 10 | 0 |
| Kachnic10 | IMRT | 2 | 24 | 95 | 94 | 94 | 7 | 10 |
3DCRT = 3D conformal radiation therapy; IMRT = intensity-modulated radiation therapy; MMC = mitomycin-C; NR = not reported.